We have data on 2,007 companies that use Illumina DNA Sequencing. The companies using Illumina DNA Sequencing are most often found in United States and in the Biotechnology industry. Illumina DNA Sequencing is most often used by companies with >10000 employees and >1000M dollars in revenue. Our data for Illumina DNA Sequencing usage goes back as far as 7 years and 7 months.
|Company||California State University, Stanislaus|
|Company||Regeneron Pharmaceuticals Inc|
|Berkeley Lab||lbl.gov||United States||200M-1000M||1000-5000|
|California State University, Stanislaus||csustan.edu||United States||100M-200M||1000-5000|
|Regeneron Pharmaceuticals Inc||regeneron.com||United States||>1000M||>10000|
|Confidential Records||confidentialrecordsinc.com||United States||0M-1M||>10000|
We use the best indexing techniques combined with advanced data science to monitor the market share of over 15,000 technology products, including Healthcare. By scanning billions of public documents, we are able to collect deep insights on every company, with over 100 data fields per company at an average. In the Healthcare category, Illumina DNA Sequencing has a market share of about 1.1%. Other major and competing products in this category include:
For DNA sequencing, Illumina's next-generation sequencing (NGS) technology uses clonal amplification and sequencing by synthesis (SBS) chemistry to enable rapid, accurate sequencing. The process simultaneously identifies DNA bases while incorporating them into a nucleic acid chain.
Looking at Illumina DNA Sequencing customers by industry, we find that Biotechnology (23%), Higher Education (22%), Hospital & Health Care (12%) and Research (11%) are the largest segments.
58% of Illumina DNA Sequencing customers are in United States and 7% are in United Kingdom.
Of all the customers that are using Illumina DNA Sequencing, a majority (51%) are large (>1000 employees), 16% are small (<50 employees) and 33% are medium-sized.
Of all the customers that are using Illumina DNA Sequencing, 41% are small (<$50M), 9% are medium-sized and 42% are large (>$1000M).